DAX-0,58 % EUR/USD0,00 % Gold-0,71 % Öl (Brent)+0,03 %

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

Nachrichtenquelle: GlobeNewswire
24.04.2019, 07:00  |  484   |   |   

Novartis International AG / Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

  • Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
  • Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
    • Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
    • Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
    • Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD 307 million, +24% cc), Kisqali (USD 91 million) and Kymriah (USD 45 million)
  • Core operating income grew 18% (cc, +9% USD) driven by the strong sales growth
  • Net income grew 4% (cc, -5% USD) impacted by a net impairment charge and lower divestment gains
  • Free cash flow[1] was USD 1.9 billion in line with prior year, which included a milestone receipt
  • Sandoz sales down 2% (cc, -8% USD) due to continued US price pressure
  • Catalyst rich 2019 with potential blockbuster launches on track:
    • Mayzent (siponimod) launched for RMS including active secondary progressive MS (SPMS)
    • Brolucizumab (RTH258) filed in the EU and US with PRV; launch in US expected within 2019
    • Zolgensma[3] (AVXS-101) new data presented at MDA supports Zolgensma as a foundation therapy
  • 2019 guidance for new focused medicines company[4] - core operating income growth revised upwards to grow high single digit (cc); sales guidance confirmed to grow mid single digit (cc)
  • In connection with the Alcon spin-off on April 9, the Group will report as part of its Q2 discontinued operations results a one-time non-cash IFRS gain of approximately USD 4.7 billion
  • Richard Saynor appointed as CEO Sandoz

Basel, April 24, 2019 - Commenting on the results, Vas Narasimhan, CEO of Novartis, said:

Seite 1 von 13
Wertpapier
Novartis
Mehr zum Thema
EuroUSDChinaJapanCap


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel